Drug intelligence / Profile preview

IDP-601

Development stage: Preclinical
Lead developer: IDP Discovery Pharma
Modality: Modified Peptides → Peptides, Small Molecules

Overview

IDP-601 is a dual inhibitor of Hypoxia-Inducible Factor-1 (HIF-1) and Hypoxia-Inducible Factor-2 (HIF-2) being developed by IDP Pharma. Utilizing the proprietary INTRAMETICS platform, IDP-601 is designed as a peptidomimetic small molecule that targets intrinsically disordered proteins (IDPs). The drug is intended to treat various solid tumors, including hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), by addressing the upregulation of both HIF-1 and HIF-2, which are associated with poor clinical prognosis and resistance to selective HIF-2 inhibitors. IDP-601 is currently in the IND-enabling stage of development.

Targets

EPAS1 (Hypoxia-inducible factor 2-alpha)HIF1A (Hypoxia-inducible factor 1-alpha)

Beyond the preview

Go deeper on IDP-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDP-601.

Explore the full profile